Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00924131
Recruitment Status : Completed
First Posted : June 18, 2009
Last Update Posted : July 2, 2017
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:


  • Researchers are greatly interested in knowing more about the long-term effects of various treatments for cancers such as Hodgkin's disease, particularly from those who have lived 20 to 30 years after treatment.
  • Patients who were treated at the National Institutes of Health (NIH) may have undergone different treatments for which more long-term information is needed.


  • To examine the body systems of long-term survivors of Hodgkin's disease to see if there are any long- term consequences of treatment for Hodgkin's disease.
  • To learn more about the long-term effects of cancer treatments.


  • Survivors of Hodgkin's disease who were previously treated at the NIH.
  • Participants must be at least 18 years of age.


  • Participants will need to sign consent forms to allow researchers to obtain documentation of medical history, including prior treatment for Hodgkin's disease and prior NIH treatment, including protocol number, where applicable:
  • Pertinent medical records, pathology reports, and radiographic imaging studies will be reviewed.
  • Primary care physician's name, address, and other contact information are also required.
  • Evaluations during the assessment period:
  • Complete physical examination.
  • Laboratory studies of blood, urine, and stool samples.
  • Radiologic evaluations, including computerized tomography (CT) and magnetic resonance imaging (MRI) scans for all participants and mammograms for females.
  • Cardiac evaluation, vascular studies, and pulmonary studies to measure heart and lung function, and digestive tests to measure stomach and intestinal function.
  • Neurocognitive testing to measure brain function.
  • Optional skin biopsy.
  • Participants will be asked to complete questionnaires assessing current quality of life and daily living skills.

Condition or disease
Hodgkin's Disease Lymphoma

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 157 participants
Time Perspective: Other
Official Title: Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial
Study Start Date : April 17, 2009
Study Completion Date : May 26, 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hodgkin Disease
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria for all Participants:

  • Patients must be at least 18 years of age 15
  • Patients must have been previously treated for Hodgkin's Disease at the NIH
  • Patient must be willing to complete quality of life questionnaires and to answer questions regarding their medical history
  • Patient must be willing to provide release of medical information forms for physicians and hospitals involved in their management

Inclusion Criteria for Evaluation at NIH/NIA:

In addition to those above,

  • Patient is willing to return to NIH/NIA to participate in the protocol
  • Patient must have a primary physician in the community who is willing to communicate with NIH regarding clinical findings and collaborate in the clinical management and follow-up of the patient. This will be substantiated by communicating directly with the patient's physician prior to evaluation.
  • Pregnant patients are eligible for follow up evaluations and quality of life evaluations. They will be excluded for any radiological testing and invasive studies. Any blood draws will be approved by the patient's obstetrician and if any of the laboratory tests to be performed have been carried out within the last three months, those values will be used instead of repeating them. Alternatively, pregnant patients may choose to participate in the study after the birth of their child to be able to participate in the full evaluation.


  • Inability to give informed consent
  • Patients, and/ or guardians who are in the estimation of the PI, deemed unable or unlikely to adhere to protocol evaluations and follow-up requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00924131

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)

Publications: Identifier: NCT00924131     History of Changes
Obsolete Identifiers: NCT00909246
Other Study ID Numbers: 090127
First Posted: June 18, 2009    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: May 26, 2010

Keywords provided by National Institutes of Health Clinical Center (CC):
Late Effects
Hodgkin's Disease
Hodgkin Disease

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases